Takahashi Kazue, Ohtani Katsuki, Larvie Mykol, Moyo Patience, Chigweshe Lorencia, Van Cott Elizabeth M, Wakamiya Nobutaka
Department of Pediatrics, Harvard Medical School, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA,
J Thromb Thrombolysis. 2014 Oct;38(3):331-8. doi: 10.1007/s11239-013-1042-5.
Collectin kidney 1 (CL-K1) is a recently identified collectin that is synthesized in most organs and circulates in blood. CL-K1 is an innate immune molecule that may play a significant role in host defense. As some collectins also play a role in coagulation, we hypothesized that an effect of CL-K1 may be apparent in disseminated intravascular coagulation (DIC), a gross derangement of the coagulation system that occurs in the setting of profound activation of the innate immune system. DIC is a grave medical condition with a high incidence of multiple organ failure and high mortality and yet there are no reliable biomarkers or risk factors. In our present study, we measured plasma CL-K1 concentration in a total of 659 specimens, including 549 DIC patients, 82 non-DIC patients and 27 healthy volunteers. The median plasma CL-K1 levels in these cohorts were 424, 238 and 245 ng/ml, respectively, with no significant difference in the latter two groups. The incidence of elevated plasma CL-K1 was significantly higher in the DIC patients compared to the non-DIC patients, resulting in an odds ratio of 1.929 (confidence interval 1.041-3.866). Infection, renal diseases, respiratory diseases, and cardiac diseases were more frequently observed in the DIC group than in the non-DIC group. In the DIC group, vascular diseases were associated with elevated plasma CL-K1 levels while age and acute illness had little effect on plasma CL-K1 levels. Independent of DIC, elevated plasma CL-K1 levels were associated with respiratory disease and coagulation disorders. These results suggest that specific diseases may affect CL-K1 synthesis in an organ dependent manner and that elevated plasma CL-K1 levels are associated with the presence of DIC. Further investigations in cohorts of patients are warranted. We propose that elevated plasma CL-K1 may be a new useful risk factor and possibly biomarker for the prediction of developing DIC.
Collectin肾1(CL-K1)是一种最近发现的凝集素,在大多数器官中合成并在血液中循环。CL-K1是一种先天免疫分子,可能在宿主防御中发挥重要作用。由于一些凝集素也在凝血中起作用,我们推测CL-K1在弥散性血管内凝血(DIC)中可能有明显作用,DIC是一种凝血系统的严重紊乱,发生在先天免疫系统深度激活的情况下。DIC是一种严重的医学状况,多器官衰竭发生率高且死亡率高,但尚无可靠的生物标志物或危险因素。在我们目前的研究中,我们共检测了659份标本中的血浆CL-K1浓度,其中包括549例DIC患者、82例非DIC患者和27名健康志愿者。这些队列中的血浆CL-K1水平中位数分别为424、238和245 ng/ml,后两组无显著差异。与非DIC患者相比,DIC患者血浆CL-K1升高的发生率显著更高,优势比为1.929(置信区间1.041-3.866)。DIC组比非DIC组更频繁地观察到感染、肾脏疾病、呼吸系统疾病和心脏疾病。在DIC组中,血管疾病与血浆CL-K1水平升高相关,而年龄和急性疾病对血浆CL-K1水平影响不大。独立于DIC,血浆CL-K1水平升高与呼吸系统疾病和凝血障碍相关。这些结果表明,特定疾病可能以器官依赖的方式影响CL-K1的合成,并且血浆CL-K1水平升高与DIC的存在相关。有必要对患者队列进行进一步研究。我们提出,血浆CL-K1升高可能是预测DIC发生的一个新的有用危险因素和可能的生物标志物。